Objective: To describe fundus autofluorescence (AF), fluorescein angiography (FA) and indocyanine green angiography (ICGA) in different types of retinal astrocytic hamartomas in tuberous sclerosis (Morbus Bourneville-Pringle). Methods: Two eyes with 8 lesions, i.e. type 1 (n = 7) and type 3 (n = 1), were examined. AF pictures were taken prior to injection, FA and ICGA images were obtained in the early and the late phase. To achieve additional cases, a systematic literature review with exten- sive Internet and library search was performed. Results: Strong AF was seen in type 2 and type 3 retinal astrocytic hamartomas, whereas type 1 lesions blocked the physiologic fundus AF. Fluorescence angiography of all types of lesions revealed hypofluorescence in early frames and hyperfluorescence originating from leakage in late frames. ICGA showed a subtle blockade in type 1, a total blockade in type 2 and in the central part and a partial blockade in the peripheral part in type 3 lesions. Conclusions: Retinal astrocytic hamartomas in tuberous sclerosis can be easily detected by angiography, especially type 1 lesions which are difficult to visualize by funduscopy. Early- and late-phase fluorescein angiography and ICGA are helpful to differentiate the three lesion types.

Keywords:
Indocyanine green angiography, Autofluorescence, Fluorescein angiography, Tuberous sclerosis, Astrocytic hamartoma
1.
Bourneville DM: Sclérose tubéreuse des circonvolution cérébrales: idiotie et épilepsie hemiphlégique. Arch Neurol (Paris) 1880;1:81–91.
2.
Shields JA, Shields CL: Systemic hamartomatoses (‘phakomatoses’); in Shields JA, Shields CL (eds): Intraocular Tumors: A Text and Atlas. Philadelphia, Saunders, 1992, pp 513–539.
3.
Van der Hoeve T: Augengeschwülste bei der tuberösen Hirnsklerose (Bourneville). Albrecht Von Graefes Arch Ophthalmol 1921;105:880–898.
4.
Nyboer JH, Robertson DM, Gomez MR: Retinal lesions in tuberous sclerosis. Arch Ophthalmol 1976;94:1277–1280.
5.
Rowley SA, O’Callaghan FJ, Osborne JP: Ophthalmic manifestations of tuberous sclerosis: a population-based study. Br J Ophthalmol 2001;85:420–423.
6.
Gündüz K, Eagle RC, Shields CL, Schields JA: Invasive giant cell astrocytomas of the retina in a patient with tuberous sclerosis. Ophthalmology 1999;106:639–642.
7.
Harley RD, Grober WD: Tuberous sclerosis: description and report of 12 cases. Ann Ophthalmol 1970;1:477–481.
8.
Gass JDM: Stereoscopic atlas of macular disease. Diagnosis and treatment. St. Louis, Mosby, 1997, pp 836–843.
9.
Kiratli H, Bilgic S: Spontaneous regression of retinal astrocytic hamartoma in a patient with tuberous sclerosis. Am J Ophthalmol 2002;133:715–716.
10.
Sahli O, Sickenberg M, Piguet B: Exudative parafoveal hamartoma associated with Bourneville tuberous sclerosis: spontaneous evolution (in French). Klin Monatsbl Augenheilkd 1997;210:332–333.
11.
Panzo GJ, Meyers SM, Gutman FA, Kollarits CR, Lederman RJ: Spontaneous regression of parafoveal exudates and serous retinal detachment in a patient with tuberous sclerosis and retinal astrocytomas. Retina 1984;4:242–245.
12.
Jost BF, Olk RJ: Atypical retinitis proliferans, retinal telangiectasis, and vitreous hemorrhage in a patient with tuberous sclerosis. Retina 1986;6:53–56.
13.
Herwig M, Laqua H: Clinical aspects and follow-up in astrocytic hamartoma of the retina and optic papilla. Klin Monatsbl Augenheilkd 1984;184:115–120.
14.
Kropinska E, Mierzejewski A, Kaluzny JJ, Kaluzna L, Nawrot M: Tuberous sclerosis – case report. Klin Oczna 2000;102:271–277.
15.
Koak N, Saatci AO, Kaynak S, Ergin MH, Ingil GC: Indocyanine green angiography of retinal astrocytomas associated with tuberous sclerosis. Korean J Ophthalmol 2003;17:145–148.
16.
Sosna T, Hamouz J: Autofluorescence as a diagnostic method. Cesk Slov Oftalmol 2002;58:340–344.
17.
Schatz H, Burton TC, Yannuzzi LA, Rabb MF: Interpretation of fundus fluorescein angiography. Saint Louis, Mosby, 1978, pp 256–257.
18.
Richard G: Fluorescein and ICG Angiography, ed 2. Stuttgart, Thieme, 1998, pp 306–307.
19.
Bloom SM, Mahl CF: Photocoagulation for serous detachment of the macula secondary to retinal astrocytoma. Retina 1991;11:416–422.
20.
Atkinson A, Sanders MD, Wong V: Vitreous haemorrhage in tuberous sclerosis. Report of two cases. Br J Ophthalmol 1973;57:773–779.
21.
Binaghi M, Coscas G, Nucci T: Retinal phacomas. Apropos of 10 cases of astrocytoma. J Fr Ophtalmol 1983;6:275–290.
22.
Gass JDM: Fluorescein angiography. An aid in the differential diagnosis of intraocular tumors. Int Ophthalmol Clin 1972;12:85–120.
23.
Fuhrmann M: Fluorescence angiography in retinal tumours (author’s transl). Klin Oczna 1981;82:577–578.
24.
Ahmad A: Fluorescein angiography in tuberous sclerosis: case report. Ann Ophthalmol 1978;10:453–455.
25.
Williams R, Taylor D: Tuberous sclerosis. Surv Ophthalmol 1985;30:143–154.
26.
Bryk E: Fluorescent angiography in a case of a retinal tumor in a case of Bourneville’s disease. Klin Oczna 1975;45:261–264.
27.
Zimmer-Galler IE, Robertson DM: Long-term observation of retinal lesions in tuberous sclerosis. Am J Ophthalmol 1995;119:318–324.
28.
Bellmann C, Rubin GS, Kabanarou SA, Bird AC, Fitzke FW: Fundus autofluorescence imaging compared with different confocal scanning laser ophthalmoscopes. Br J Ophthalmol 2003;87:1381–1386.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.